Aurobindo Pharma Receives Clean USFDA Inspection at Andhra Facility
Aurobindo Pharma said the US Food and Drug Administration completed an inspection of its Andhra Pradesh manufacturing facility with zero observations. The clean outcome indicates the plant met USFDA standards, supporting continued ability to supply medicines to the US market. The update comes amid other USFDA reviews of the group’s facilities this year, including observations at Unit-VI of Apitoria Pharma.